Spurious hypercalcitoninemia in patients with nodular thyroid disease induced by heterophilic antibodies

Head and Neck

Volumn 32, Issue 1, 2010, Pages 68-75

  Kim, Jung Min ^a   Chung, Ki Wook ^a   Kim, Seok Won ^a   Choi, Seon Hyeong ^b   Min, Hye Sook ^a   Kim, Ji Na ^a   Won, Woo Jae ^a   Kim, Seok Ki ^a   Lee, Ji In ^c   Chung, Jae Hoon ^c   Kim, Sun Wook ^c  

^a National Cancer Center   (South Korea)

^b Hallym University   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Calcitonin; Heterophilic antibody; Hypercalcitoninemia; Interference; Medullary thyroid carcinoma

Indexed keywords

CALCITONIN; CALCIUM; HETEROPHILE ANTIBODY;

ADULT; ARTICLE; ASPIRATION BIOPSY; CALCITONIN BLOOD LEVEL; CASE REPORT; DIAGNOSTIC KIT; ENDOCRINE DISEASE; FEMALE; HUMAN; HYPERCALTINONINEMIA; PRIORITY JOURNAL; PROVOCATION TEST; THYROID MEDULLARY CARCINOMA; THYROID NODULE; THYROIDECTOMY;

ADULT; ALGORITHMS; ANTIBODIES, HETEROPHILE; BIOPSY, FINE-NEEDLE; CALCITONIN; CARCINOMA, MEDULLARY; EARLY DIAGNOSIS; FEMALE; HUMANS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; THYROID NODULE; THYROIDECTOMY; THYROIDITIS, AUTOIMMUNE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 75149197312     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21145     Document Type: Article

References (47)

1. Cohen R, Campos JM, Salaun C, et al. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC). J Clin Endocrinol Metab 2000;85:919-922.
2. Jackson CE, Talpos GB, Kambouris A, Yott JB, Tashjian AH Jr, Block MA. The clinical course after definitive operation for medullary thyroid carcinoma. Surgery 1983;94:995-1001.
3. Melvin KE, Miller HH, Tashjian AH Jr. Early diagnosis of medullary carcinoma of the thyroid gland by means of calcitonin assay. N Engl J Med 1971;285:1115-1120.
4. Wells SA Jr, Baylin SB, Leight GS, Dale JK, Dilley WG, Farndon JR. The importance of early diagnosis in patients with hereditary medullary thyroid carcinoma. Ann Surg 1982;195:595-599.
5. Elisei R, Bottici V, Luchetti F, et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 2004;89:163-168.
6. Hahm JR, Lee MS, Min YK, et al. Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases. Thyroid 2001;11:73-80.
7. Iacobone M, Niccoli-Sire P, Sebag F, De Micco C, Henry JF. Can sporadic medullary thyroid carcinoma be biochemically predicted? Prospective analysis of 66 operated patients with elevated serum calcitonin levels. World J Surg 2002;26:886-890.
8. Castro MR, Gharib H. Continuing controversies in the management of thyroid nodules. Ann Intern Med 2005;142:926-931.
9. Hodak SP, Burman KD. The calcitonin conundrum-is it time for routine measurement of serum calcitonin in patients with thyroid nodules? J Clin Endocrinol Metab 2004;89:511-514.
10. Horvit PK, Gagel RF. The goitrous patient with an elevated serum calcitonin-what to do? J Clin Endocrinol Metab 1997;82:335-337.
11. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109-142.
12. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787-803.
13. Uwaifo GI, Remaley AT, Stene M, et al. A case of spurious hypercalcitoninemia: a cautionary tale on the use of plasma calcitonin assays in the screening of patients with thyroid nodules for neoplasia. J Endocrinol Invest 2001;24:361-369.
14. Papapetrou PD, Polymeris A, Karga H, Vaiopoulos G. Heterophilic antibodies causing falsely high serum calcitonin values. J Endocrinol Invest 2006;29:919-923.
15. Tommasi M, Brocchi A, Cappellini A, Raspanti S, Mannelli M. False serum calcitonin high levels using a non-competitive two-site IRMA. J Endocrinol Invest 2001;24:356-360.
16. Kricka LJ. Human anti-animal antibody interferences in immunological assays. Clin Chem 1999;45:942-956.
17. Levinson SS, Miller JJ. Towards a better understanding of heterophile (and the like) antibody interference with modern immunoassays. Clin Chim Acta 2002;325:1-15.
18. Preissner CM, O'Kane DJ, Singh RJ, Morris JC, Grebe SK. Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays. J Clin Endocrinol Metab 2003;88:3069-3074.
19. Pacini F, Fontanelli M, Fugazzola L, et al. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1994;78:826-829.
20. Niccoli P, Wion-Barbot N, Caron P, et al. Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group. J Clin Endocrinol Metab 1997;82:338-341.
21. Rieu M, Lame MC, Richard A, et al. Prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules. Clin Endocrinol (Oxf) 1995;42:453-460.
22. Vierhapper H, Raber W, Bieglmayer C, Kaserer K, Weinhausl A, Niederle B. Routine measurement of plasma calcitonin in nodular thyroid diseases. J Clin Endocrinol Metab 1997;82:1589-1593.
23. Niccoli P, Conte-Devolx B, Lejeune PJ, et al. Hypercalcitoninemia in conditions other than medullary cancers of the thyroid. Ann Endocrinol (Paris) 1996;57:15-21.
24. Boscato LM, Stuart MC. Heterophilic antibodies: a problem for all immunoassays. Clin Chem 1988;34:27-33.
25. Despres N, Grant AM. Antibody interference in thyroid assays: a potential for clinical misinformation. Clin Chem 1998;44:440-454.
26. Kricka LJ. Interferences in immunoassay - still a threat. Clin Chem 2000;46(8 Part 1):1037-1038.
27. Levinson SS. Antibody multispecificity in immunoassay interference. Clin Biochem 1992;25:77-87.
28. Kaplan IV, Levinson SS. When is a heterophile antibody not a heterophile antibody? When it is an antibody against a specific immunogen. Clin Chem 1999;45:616-618.
29. Kazmierczak SC, Catrou PG, Briley KP. Transient nature of interference effects from heterophile antibodies: examples of interference with cardiac marker measurements. Clin Chem Lab Med 2000;38:33-39.
30. Wickus GG, Caplan RH, Mathews EA, Pehling GB. Sudden appearance and subsequent disappearance of interference in immunometric assays of thyrotropin neutralizable with purified mouse IgG. Clin Chem 1991;37:595-596.
31. Ballow M, Nelson R. Immunopharmacology: immunomodulation and immunotherapy. JAMA 1997;278:2008-2017.
32. Wilder RB, DeNardo GL, DeNardo SJ. Radioimmunotherapy: recent results and future directions. J Clin Oncol 1996;14:1383-1400.
33. Sosolik RC, Hitchcock CL, Becker WJ. Heterophilic antibodies produce spuriously elevated concentrations of the MB isoenzyme of creatine kinase in a selected patient population. Am J Clin Pathol 1997;107:506-510.
34. Hennig C, Rink L, Fagin U, Jabs WJ, Kirchner H. The influence of naturally occurring heterophilic anti-immunoglobulin antibodies on direct measurement of serum proteins using sandwich ELISAs. J Immunol Methods 2000;235:71-80.
35. Kuroki M, Matsumoto Y, Arakawa F, et al. Reducing interference from heterophilic antibodies in a two-site immunoassay for carcinoembryonic antigen (CEA) by using a human/mouse chimeric antibody to CEA as the tracer. J Immunol Methods 1995;180:81-91.
36. Norden AG, Jackson RA, Norden LE, Griffin AJ, Barnes MA, Little JA. Misleading results from immunoassays of serum free thyroxine in the presence of rheumatoid factor. Clin Chem 1997;43(6 Part 1):957-962.
37. Ward G, McKinnon L, Badrick T, Hickman PE. Heterophilic antibodies remain a problem for the immunoassay laboratory. Am J Clin Pathol 1997;108:417-421.
38. Morgan BR, Tarter TH. Serum heterophile antibodies interfere with prostate specific antigen test and result in over treatment in a patient with prostate cancer. J Urol 2001;166:2311-2312.
39. Emerson JF, Ngo G, Emerson SS. Screening for interference in immunoassays. Clin Chem 2003;49:1163-1169.
40. Bertholf RL, Johannsen L, Guy B. False elevation of serum CA-125 level caused by human anti-mouse antibodies. Ann Clin Lab Sci 2002;32:414-418.
41. Ismail AA. A radical approach is needed to eliminate interference from endogenous antibodies in immunoassays. Clin Chem 2005;51:25-26.
42. Ismail AA, Walker PL, Cawood ML, Barth JH. Interference in immunoassay is an underestimated problem. Ann Clin Biochem 2002;39(Part 4):366-373.
43. Butler SA, Cole LA. Use of heterophilic antibody blocking agent (heterophilic blocking tube) in reducing falsepositive hCG results. Clin Chem 2001;47:1332-1333.
44. Preissner CM, Dodge LA, O'Kane DJ, Singh RJ, Grebe SK. Prevalence of heterophilic antibody interference in eight automated tumor marker immunoassays. Clin Chem 2005;51:208-210.
45. Ellis MJ, Livesey JH. Techniques for identifying heterophile antibody interference are assay specific: study of seven analytes on two automated immunoassay analyzers. Clin Chem 2005;51:639-641.
46. Cantor D. Reason for limitations of heterophilic blocking tube use on certain beckman coulter access assays. Clin Chem 2005;51:1311.
47. Costante G, Meringolo D, Durante C, et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab 2007;92:450-455.